S18-000003 is a novel, potent and orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitor with the potential to be used for psoriasis with low risk of thymic aberrations.

Cedirogant (also known as ABBV-157) is a novel and orally active RORγt inverse agonist.

SR-0987 is a T cell-specific RORγ (RORγt) agonist.

Cintirorgon (formerly also known as LYC55716; LYC-55716), a novel and potent immune modulatory medicine developed by Lycera, is a synthetic and orally bioavailable small molecule agonist of RAR-related orphan receptor γ (RORγ).

SR3335 (also known as ML-176) is a novel and selective RORα inverse agonist with a Ki of 220 nM.

SR-1078 is a selective agonist of RORα and RORγ that stimulates ROR transcriptional activity in HEK293 cell reporter assays at concentrations as low as 2 µM without effect at the related liver X receptors and farnesoid X receptors.

GSK805 (GSK-805) is a novel, potent, and orally bioavailable RORγt inhibitor with the potential to be used for autoimmune encephalomyelitis (EAE).

SR1001 (SR-1001) is a novel, potent and selective antagonist/inhibitor/inverse agonist of the nuclear retinoic acid receptor-related orphan receptors RORα and RORγ with immunomodulatory effects.

PF-06747711 (PF06747711) is a novel, potent, selective, and orally bioactive retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist with anti-skin inflammatory activity.

TMP778 (TMP-778; TMP 778) is a novel and potent RORγt inverse agonist with potential anti-inflammatory activity.